Something seems a little different from a few years ago when you walk into a McDonald’s on a weekday afternoon. In some places, the lines are a bit shorter. Once an automatic upgrade for a significant portion of the lunch crowd, the enormous combo orders now seem a little less automatic. Inflation might be the cause. It might be changing preferences. It might be the general economic strain that has been reducing discretionary spending for the past two years. Alternatively, it might be a completely different condition that begins with a weekly injection and ends with a person not being sufficiently hungry to finish their fries.
When Wall Street made its decision on that matter in 2023, the outcome was startling. As traders wagered that GLP-1 medications, such as Ozempic, Wegovy, Mounjaro, and their growing pharmaceutical family, would permanently suppress American appetite in ways that would manifest on restaurant revenue lines, short interest in restaurant stocks surged to $12.2 billion.
| Category | Details |
|---|---|
| Drug at the Center | Ozempic (semaglutide) by Novo Nordisk — originally approved for type 2 diabetes; now widely used for weight loss alongside Wegovy |
| Wall Street Reaction | Short interest in restaurant stocks swelled to $12.2 billion by October 2023; traders expanded short bets by $815 million in 30 days, per S3 Partners data |
| Stocks Under Pressure | McDonald’s, Chipotle Mexican Grill, Starbucks — all saw significant increases in short positions as GLP-1 drug adoption rose |
| Restaurant Index Drop | S&P 500 Restaurant Sub Industry Index fell approximately 12% in three months at peak Ozempic short-selling wave (late 2023) |
| Grocery Spending Change | Cornell University research (Dec 2025): within six months of starting a GLP-1 drug, households reduce grocery spending by an average of 5.3% |
| Snack Industry Impact | Snacking — previously the fastest-growing packaged food category — is losing momentum; consumers shifting toward protein products and away from cookies, chips, and confectionery |
| Walmart Signal | Walmart’s U.S. CEO noted early signs that customers using appetite-suppressing GLP-1 drugs were pulling back on food spending — one of the first major retail confirmations of the trend |
| Barclays Recommendation | British bank Barclays explicitly recommended shorting fast-food credit, citing GLP-1 drugs as a structural risk to demand for high-calorie menu items |
| McDonald’s Downgrade | McDonald’s received a stock downgrade from analysts in June 2025 partly tied to concerns that weight-loss drug adoption could durably suppress fast-food demand |
| Broader Sectors at Risk | Beyond restaurants: snack food manufacturers, cigarette companies (appetite and addiction links), certain gym and fitness equipment categories, and large-format grocery retail |
| Counterargument | Many analysts caution that GLP-1 adoption is still a fraction of the population; economic pressures, inflation, and shifting consumer preferences are contributing independently to food spending changes |
| Novo Nordisk Market Position | Novo Nordisk briefly became Europe’s most valuable company by market cap during the Ozempic boom — an unprecedented position for a pharmaceutical firm on that continent |
According to data from analytics firm S3 Partners, short bets against businesses like McDonald’s, Chipotle, and Starbucks increased by $815 million in a single 30-day period. At the peak of the wave, the S&P 500 Restaurant Sub Industry Index fell about 12% over three months. This was a novel and unfamiliar threat to an industry that had spent years managing labor costs, supply chain disruptions, and the unique chaos of post-pandemic consumer behavior. It’s not a supply issue. a problem with demand. a biological one.
Investors were essentially pricing in the possibility that a pharmaceutical product could actually, measurably reduce the amount of food consumed by Americans, something that decades of public health campaigns, school nutrition programs, and celebrity diet culture had all failed to do. There has been a steady stream of evidence that this is taking place, at least on the periphery.
In December 2025, Cornell University researchers reported that households cut their grocery spending by an average of 5.3% within six months of beginning a GLP-1 medication. Early indications of the trend were noted by Walmart’s U.S. CEO, who pointed out that consumers using appetite suppressants were avoiding certain food categories. Something has truly changed when the biggest retailer in the nation begins keeping an eye on a pharmaceutical class’s dietary side effects.
In particular, snacking reveals a lot. Snacking was the fastest-growing packaged food category for the majority of the last ten years. Food conglomerates invested acquisition funds in this market, assuming that Americans would always eat smaller, more frequent meals. There is now a lot of pressure on that thesis. While protein shakes and bars continue to gain popularity, cookies, pretzels, and confections are losing ground. This may be a reflection of GLP-1 effects, where the impulse-driven, low-satiety snack is most negatively impacted because the between-meal craving is eliminated by appetite suppression. Ozempic may be receiving a disproportionate amount of credit, but it’s also possible that economic pressure and a general wellness consciousness are doing the majority of the work. Both are most likely true, and it’s more difficult to distinguish between them than the headlines imply.
Some investors believe that Wall Street might be ahead of the real data in this case. Despite the widespread use of GLP-1 medications, only a small portion of the population still uses them, and that portion is relatively wealthy considering the price of branded versions. In hindsight, the wave of short sales that affected restaurants in 2023 appeared to be a little premature; some of those stocks recovered as actual revenue figures proved to be more robust than the bear case forecast.
Due in part to Ozempic concerns, analysts downgraded McDonald’s in June 2025. Depending on how widely these drugs penetrate lower-income demographics over the next ten years, this kind of call could age very well or very poorly. Anyone who expresses a high level of confidence about that variable is likely overestimating our level of knowledge because it is genuinely uncertain.
The direction appears to be less ambiguous. During the drug’s rise, Novo Nordisk, the Danish company that makes Ozempic and Wegovy, momentarily rose to the top of the European market capitalization rankings. This was an almost unbelievable achievement for a pharmaceutical company that most Europeans had never heard of five years prior. That type of market position’s economic gravity tends to draw capital, competition, and ultimately lower prices. The number of people using GLP-1 medications may increase significantly in the coming years if biosimilar competition or legislative changes make them much more affordable. At that point, the 5.3% decrease in grocery spending is applied to a much larger base, making it a much larger number.
Observing this unfold in quarterly earnings calls and analyst notes, there’s something truly unique about an industry reckoning motivated by a medication that reduces hunger rather than a rival or a change in regulations. For generations, the food industry has worked to make its products as hard to stop eating as possible. For the first time, it might be up against something more difficult to out-engineer than a superior chip flavor.
